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me are honored to provide readers of the Journal with this
eview of major scientific work published in the field of
nterventional cardiology in 2008. In addition, we have
ncluded late-breaking trials presented at the American
ollege of Cardiology (ACC), Transcatheter Cardiovascu-
ar Therapeutics, and American Heart Association (AHA)
onferences. We hope that this report will provide a broad
verview of the field for general cardiologists, as well as a
ramework for more detailed study for those with a specific
nterest in interventional cardiology.
ercutaneous Coronary Intervention (PCI)
uideline Update
n update of the ACC/AHA/Society for Cardiac Angiog-
aphy and Interventions 2005 Guideline Update for PCI
as published early in 2008 (1). This focused update
rovides revisions to existing guideline recommendations
ased on new clinical trial data and opinion in this rapidly
volving field. The document highlights certain key areas,
ncluding unstable angina/non–ST-segment elevation myo-
ardial infarction (NSTEMI), facilitated PCI, rescue PCI,
CI after fibrinolysis, ancillary therapy for ST-segment eleva-
ion myocardial infarction (STEMI), antiplatelet therapy,
are-metal stents (BMS) and drug-eluting stents (DES), and
nally, secondary prevention. Full review of the updated
uideline recommendations is beyond the scope of this article.
areful reading of this document is essential for all those
nvolved in the practice of interventional cardiology.
cute Myocardial Infarction (AMI)
TEMI update. The ACC/AHA STEMI guidelines were
evised and published as a focused update in 2008 (2).
ssential changes in the guidelines include: 1) emphasis on
re-hospital electrocardiography and transport of STEMI
atients directly to a PCI facility (bypassing hospitals that
re not PCI capable); 2) facilitated PCI with full-dose
hrombolytic agents may be harmful (Class IIIb); 3) clopi-
ogrel should be added to aspirin in STEMI patients
egardless of reperfusion status (Class Ia) and long-term
rom *William Beaumont Hospital, Royal Oak, Michigan; and the †University of
iami, Miami, Florida. Dr. Dixon is a consultant for Abiomed Inc. Dr. Grines is a consultant
or Pfizer, Sanofi-Synthelabo, Bristol-Myers Squibb, and the GlaxoSmithKline Globalm
ardiovascular Board. Dr. O’Neill is a consultant for Medtronic.
Manuscript received February 7, 2009; accepted February 18, 2009.aintenance (e.g., 1 year) is reasonable (Class IIa, Level of
vidence: C); 4) intravenous beta-blockers should not be
iven to STEMI patients with signs of congestive heart
ailure (CHF) or low cardiac output (Class IIIa); 5) non-
teroidal anti-inflammatory drugs (except for aspirin)
hould not be given (Class IIIc); and 6) routine coronary
ngiography may be considered after thrombolytic therapy
n patients not receiving reperfusion therapy (Class IIb)
ith PCI of a hemodynamically significant stenosis in a
atent vessel (Class IIb). However, late PCI of a totally
ccluded infarct artery is not recommended in asymptom-
tic patients who are hemodynamically and electrically
table and do not have ischemia. Stone (3,4) provided an
xcellent 2-part review article on primary angioplasty.
egional care systems. Several groups reported findings
fter development of regional systems for STEMI care. Le
ay et al. (5) reported that acceptable door-to-balloon
imes are more often achieved when paramedics triage and
ransport STEMI patients directly to a PCI center com-
ared with patient referral from the emergency department.
guirre et al. (6), Flesch et al. (7), and Holmes et al. (8)
howed that timely mechanical reperfusion can be achieved
or patients initially presenting to a non-PCI center, with
ell-organized transfer protocols and coordinated systems
f care.
ime to treatment. Excessive delay to primary PCI con-
inues to be an issue, especially when the patient presents to
non-PCI facility. The National Cardiovascular Data
egistry (NCDR) (9) reported that 15,049 patients at 491
ospitals underwent primary PCI after being transferred
rom a non-PCI facility between 2005 and 2006 (the
edian door-to-balloon time was 152 min (door-to-door:
09 min and PCI hospital door-to-balloon: 38 min). Al-
hough the delay was shortened compared with earlier years
180 min), there remains room for improvement. The Get
ith the Guidelines database (10) reported 62,814 AMI
atients, of whom 5,649 arrived during off hours (nights,
eekends, and holidays). Although off-hour patients had
onger door-to-balloon times (110 min vs. 85 min, p 
.001), no measurable differences were found in mortality.
uality of care. Two important ACC/AHA reports on
erformance measures for patients with STEMI and
STEMI were published in 2008 (11,12). These docu-
ents are an update of the ACC/AHA report on perfor-
ance measures in 2006. Key changes include: deletion of
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June 2, 2009:2080–97 Year in Interventional Cardiologyeta-blocker on arrival, revision of 9 measures, and addition
f 4 new measures, including evaluation of left ventricular
LV) systolic function, time to transfer and time to PCI for
TEMI patients presenting initially to a facility without
CI, and inpatient referral for cardiac rehabilitation. The
econd article focuses on measurement of time to reperfu-
ion, and provides clarification on specific inclusions and
xclusions for this measure, as well as the time point when
eperfusion is achieved. Readers are encouraged to examine
hese documents for more detail.
In other articles, Glaser et al. (13) examined factors
ontributing to the worse prognosis of STEMI patients
resenting during off hours, and found that this seemed to
e related to both diurnal differences in patient and lesion
haracteristics (e.g., more shock and multivessel disease), as
ell as increased risk of procedural complications (13). Lev
t al. (14) compared the predictive value of 4 different risk
cores and found that the CADILLAC (Controlled Abcix-
mab and Device Investigation to Lower Late Angioplasty
omplications), Thrombolysis In Myocardial Infarction,
nd PAMI (Primary Angioplasty in Myocardial Infarction)
isk scores all had a high predictive accuracy for 30-day and
-year mortality; however, the Global Registry of Acute
oronary Events risk score had a low predictive value for
utcomes.
CI after thrombolysis. The CARESS in AMI (Com-
ined Abciximab Retaplase Stent Study in Acute Myocar-
ial Infarction) trial (7) treated 600 STEMI patients 75
ears of age with half-dose retaplase, abciximab, aspirin, and
eparin, then randomized to immediate transfer for PCI
ersus transfer only for rescue PCI (persistent ST-segment
levation) (15). The combined end point of death, myocar-
ial infarction (MI), or refractory ischemia was improved in
he immediate PCI group (4.4% vs. 10.7%, p  0.004);
owever, bleeding was increased. In a large French registry,
arly PCI after full-dose thrombolysis was associated with
imilar 1-year survival to primary PCI alone (16).
acilitated PCI. Although facilitated PCI with full-dose
hrombolytic agents was found to be harmful, Denktas et al.
17) found that facilitation with reduced-dose thrombolytic
gents was safe and effective in a nonrandomized observa-
ional experience. A large randomized trial comparing
alf-dose retaplase plus abciximab had improved ST-
egment resolution but no improvement in clinical out-
omes to primary PCI (18). Several randomized trials
nvestigated the use of glycoprotein (GP) IIb/IIIa agents for
acilitated PCI. Consistently, there was no improvement
ver primary PCI in randomized comparisons with pre-
ospital eptifibatide (19), tirofiban (20), or abciximab (18).
hese data confirm previous reports that primary PCI
ithout facilitation is the strategy of choice.
P IIb/IIIa inhibitors. A previous meta-analysis sug-
ested improved mortality using abciximab during primary
CI. The FATA (Facilitated Angioplasty with Tirofiban or
bciximab) trial randomized 738 patients to abciximabersus tirofiban and found better ST-segment resolution in 3he abciximab group (21). Although abciximab has been
hown to reduce stent thrombosis and acute ischemia, a
andomized trial of 800 primary PCI patients found no
mprovement in infarct size with abciximab compared with
lacebo (22). In another randomized trial, intracoronary
bciximab bolus (followed by 12-h intravenous infusion)
as superior to intravenous bolus and infusion at improving
erfusion and reducing infarct size after primary PCI (23).
Although STEMI studies showing the benefits of GP
Ib/IIIa agents have used abciximab, eptifibatide is used
ore frequently because of cost concerns. In a retrospective
nalysis of 3,541 STEMI patients undergoing primary PCI
se of eptifibatide (n  2,812) compared with abciximab
n  729) resulted in similar rates of in-hospital death, MI,
r stroke (24). In a retrospective analysis of patients receiv-
ng bolus only (n  1,565) compared with bolus plus
nfusion (n  1,064) of GP IIb/IIIa showed similar isch-
mic outcomes, but reduced bleeding and cost compared
ith the bolus-only strategy (25).
ivalirudin. Bivalirudin was found to be superior to hep-
rin (either enoxaparin or unfractionated heparin [UFH])
lus GP IIb/IIIa agents in the HORIZONS AMI (Har-
onizing Outcomes with Revascularization and Stents in
cute Myocardial Infarction) trial. Despite an increased risk
f acute stent thrombosis with bivalirudin, bleeding and
linical outcomes were improved at 1 month (26) and
emained significant at 1 year.
ES. Several registries of DES for AMI found clinical
vent rates that were similar to (27) or superior to those for
MS (28–31). An editorial suggested a need for better large
andomized trials and longer follow-up to address late stent
hrombosis and poor patient compliance with medication (32).
Kelbæk et al. (33) randomized 625 STEMI patients to
ES versus BMS. At 8 months, angiographic restenosis
nd target lesion revascularization (TLR) were improved
ith DES; however, there was a trend for higher mortality.
an der Hoeven et al. (34) found that sirolimus-eluting
tents (SES) reduced angiographic restenosis and TLR but
ere associated with a higher incidence of late stent malappo-
ition. Valgimigli et al. (35) randomized 745 STEMI patients
o SES versus BMS and found reduced major adverse cardiac
vents (MACE) at 8 months. The HORIZONS AMI trial
andomized 3,006 patients to paclitaxel-eluting stents (PES)
ersus BMS; PES was superior at reduction in angiographic
estenosis and TLR at 1 year (4.5% vs. 7.5%, p  0.002) with
imilar rates of stent thrombosis, MI, and death (36). Lee (37)
andomized 328 STEMI patients to zotarolimus-eluting stent
ZES), SES, or PES. Angiographic restenosis was significantly
ower with SES compared with other DES; however, clinical
utcomes were similar. These data add to the evidence that
ES reduce target vessel revascularization (TVR) after pri-
ary PCI, and in the short term, seem to be safe.
ate reperfusion. There is still controversy about the role
f PCI in patients presenting late after the onset of AMI
12 h). Abbate et al. (38) performed a meta-analysis of
,560 patients undergoing PCI versus medical therapy
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Year in Interventional Cardiology June 2, 2009:2080–97lone. Late PCI (median 12 days) was associated with a
ignificant improvement in survival (mortality 6.3% vs.
.4%, odds ratio [OR]: 0.49, p  0.03) and favorable effect
n ventricular function and remodeling. In contrast, the
AT (Occluded Artery Trial) investigators (39) found no
enefit of late reperfusion for persistent infarct artery
cclusion in stable patients 3 to 28 days after MI.
istal embolization. Distal embolization is common dur-
ng infarct angioplasty. Using a Doppler guidewire, Oka-
ura et al. (40) showed that embolization occurs most
requently after stenting, followed by first balloon inflation.
ntil now, however, most studies have shown little or no
enefit of routine thrombectomy in AMI. In the largest trial
o date, Svilaas et al. (41) randomized 1,071 AMI patients
o adjunctive thrombus aspiration with the 6-F Export
atheter (Medtronic, Minneapolis, Minnesota) versus con-
entional PCI. Thrombus aspiration was associated with a
ignificant improvement in myocardial blush and ST-
egment resolution. At 1 year, the thrombus-aspiration
roup also had a lower incidence of death or re-infarction
42). In another smaller randomized trial, VAMPIRE
VAcuuM asPIration thrombus REmoval), thrombus aspi-
ation was also associated with an improved rate of myo-
ardial blush grade 3, and lower MACE rate at 8 months
43). Vlaar et al. (44) also compared the effectiveness of 2
spiration catheters (Diver [Invatec, Roncadelle, Italy] ver-
us Export [Medtronic]) and found no difference in size
istribution of retrieved thrombotic particles with either
evice.
A small randomized trial evaluating use of embolic
rotection showed improved ST-segment resolution in
atients treated with a proximal occlusion device (45). In
ontrast, Kelbæk et al. (46). found no benefit of distal
mbolic protection with the FilterWire device (Boston
cientific, Santa Clara, California). Dangas et al. (47) also
eported that distal protection does not seem to be beneficial
n rescue PCI. Finally, Kramer et al. (48) performed
istological analysis of aspirated material in 1,315 AMI
atients, and found that older thrombus (1 day) was an
ndependent predictor of long-term mortality.
djunctive therapies. Several studies in 2008 investigated
ovel pharmacologic or mechanical adjuncts to limit myo-
ardial injury in AMI. In a small pilot trial, 58 patients were
andomized to receive intravenous cyclosporine or saline
mmediately before PCI. Infarct size, measured by release of
reatine kinase, troponin I, and magnetic resonance imaging
n a subgroup, was significantly smaller in patients who
eceived cyclosporine (49). In another trial, intracoronary
AI-9803 in anterior MI patients with total occlusion of
he left anterior descending artery (LAD) led to favorable
mprovements in ST-segment resolution, creatine kinase
elease kinetics, myocardial perfusion grade, and infarct size
50). Ishii et al. (51) provided a review article summarizing
he role of various other pharmacologic adjuncts to reper-
usion therapy, including adenosine, atrial natriuretic pep-
ide, nicorandil, and statins. Left ventricular unloading ieems to be another promising strategy for reducing infarct
ize. Sjauw et al. (52) studied the effect of unloading with
he Impella 2.5 (Abiomed, Danvers, Massachusetts) percu-
aneous LV assist device in nonshock anterior AMI. Pa-
ients treated with the Impella 2.5 device had a greater
mprovement in LV ejection fraction at 4 months compared
ith a control group.
ardiogenic shock. Seyfarth et al. (53) reported results of
small randomized trial evaluating the Impella 2.5 device in
ardiogenic shock. Compared with intra-aortic balloon
ump, patients treated with the Impella 2.5 device had a
igher cardiac index and less lactic acidosis. An interesting
eport from Apolito et al. (54) suggests that public reporting
f outcome data may deter physicians from providing
evascularization to shock patients. In this analysis, New
ork patients were less likely to receive angiography or PCI,
nd also waited significantly longer to receive a coronary
rtery bypass graft (CABG) than non-New York patients
ith shock. Reynolds et al. (55) provided a comprehensive
eview article of etiology, pathophysiology, and contempo-
ary treatment of cardiogenic shock complicating AMI.
ell therapy. Two meta-analyses examined the concept of
tem cell therapy after AMI. Zohlnhöfer et al. (56) reported
0 trials that randomized 445 patients to control versus
ranulocyte colony stimulating factor to augment the num-
er of circulating stem cells after AMI. There was no
ignificant difference in infarct size and ejection fraction
etween the treatment groups. Conversely, selective infu-
ion of stem cells into the infarct artery resulted in improved
jection fraction and reduced infarct size in a meta-analysis
f 13 trials and 811 patients (57).
cute Coronary Syndromes (ACS)
teg et al. (58) studied outcomes in patients with NSTEMI
nd CHF in the Global Registry of Acute Coronary Events.
atients with CHF were less likely to undergo revascular-
zation than those without CHF. After adjustment for
ifferences in baseline risk, revascularized patients had lower
-month mortality, suggesting that broader use of PCI in
hese high-risk patients may be beneficial. Ndrepepa et al.
59) reported 1-year outcomes of the ISAR-REACT 2
Intracoronary Stenting and Antithrombotic Regimen–
apid Early Action for Coronary Treatment 2) randomized
rial. In high-risk patients with NSTEMI undergoing PCI
fter pre-treatment with 600 mg clopidogrel, adverse events
ccurred less frequently with abciximab. Mehta (60) pre-
ented results of a randomized trial of an early (within 24 h
f symptom onset) versus delayed (36 h) invasive strategy
n high-risk ACS patients. The early strategy did not reduce
he incidence of the composite end point of death, MI, or
troke at 6 months; however, there was a reduction in the
ncidence of refractory ischemia in the early invasive arm.
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eft main disease. Current American and European
uidelines recommend CABG for unprotected left main
ULM) disease, with PCI reserved only for patients who are
igh risk, inoperable, or refuse surgery. Taggart et al. (61)
ummarized the surgical consensus, namely that CABG is
roven therapy, and that PCI has limited value and may
ven be inferior to medical therapy for patients not suitable
or surgery. Teirstein (62) provided a more balanced over-
iew, and pointed out that numerous unanswered questions
emain before routine PCI of ULM disease can be
ecommended.
In 2008, a number of registries and randomized trials
egan to provide clarity on the role of ULM PCI. Biondi-
occai et al. (63) performed a meta-analysis of 16 studies of
ES implantation for ULM disease. Among 1,278 patients
reated with a DES, in-hospital and 6-month mortality
ere 2.3% and 5.5%, respectively. The MACE and TVR
ates were significantly lower in ostial and shaft lesions
ersus distal bifurcation disease. The rate of MACE was
ower for DES compared with BMS, driven mainly by a
ower rate of restenosis and TVR. The DELFT (Drug
luting stent for LeFT main) registry (64) reported out-
omes for 358 consecutive patients with ULM disease.
rocedural success was 89.6%, and in-hospital mortality was
%. Overall 3-year mortality was 9.2%.
The optimal technical approach to distal left main stent-
ng is unclear. Palmerini et al. (65) provided data from a
arge, multicenter Italian registry in which 773 patients
nderwent PCI for distal left main disease (1 stent in 456
atients, 2 stents in 317). The adjusted 2-year survival was
ignificantly better for the single- versus 2-stent strategy.
hen 2 stents were used, there was no difference between
rush versus T-stent versus culotte techniques. Thus, like
ther bifurcation disease, distal left main disease should be
reated with single stent implantation if technically possible.
Mehilli (66) presented results of a randomized trial of
ES versus PES in 607 low-risk patients with ULM disease
ISAR-LEFT MAIN [Intracoronary Stenting and An-
iograpic Results: Drug Eluting Stents for Unprotected
oronary Left Main Lesions]). The primary end point,
-year MACE, was similar between SES- and PES-treated
atients (15.8% vs. 13.6%). Angiographic restenosis was
lso similar (19.4% vs. 16.0%).
Several nonrandomized comparisons of PCI versus
ABG for ULM disease were published in 2008. Seung
t al. (67) reported outcomes in 2,240 patients treated with
CI or CABG from January 2000 to June 2006. In this
atched comparison, there was no difference in long-term
ortality or the composite of death, MI, or stroke, but a
igher rate of TVR was observed in patients treated with
CI. Other studies also reported similar survival between
CI- and CABG-treated patients (68–70). White et al.
71) provided further insight by stratifying outcomes ac-
ording to baseline risk. Survival was similar for low-risk 0atients. However, survival was lower among high-risk
atients treated with PCI. In aggregate these registries
uggest equipoise for low-risk patients with ULM disease
nd provide an excellent foundation for several recently
ompleted randomized trials.
The first of these randomized trials is the Polish LE MANS
Study of Unprotected Left Main Stenting Versus Bypass
urgery) trial (72). Buszman et al. (72) randomized 105
ow-risk patients (age 60 years, LV ejection fraction 53%)
nd found greater improvement in late LV ejection fraction
3.3  6.7% vs. 0.5  0.8%, p  0.047) for PCI-treated
atients compared with CABG.
Serruys (73) presented results of the left main subset of
he SYNTAX (Synergy between Percutaneous Coronary
ntervention with Taxus and cardiac surgery) study (348
atients randomized to CABG, 357 randomized to Taxus
tent implantation [Boston Scientific, Minneapolis, Minne-
ota]). Patients were low risk (Euroscore 3.9, age 65 years,
5% male). At 1 year, mortality was similar in both arms
4.4% CABG vs. 4.2% PCI, p  NS), but there was a
igher incidence of stroke in the CABG group (2.7% vs.
.3%, p  0.009). Repeat revascularization at 1 year was
igher in the PCI arm (12.0% vs. 6.7%, p  0.02). The
ombination of these registries and the SYNTAX trial now
llow clinicians to make more scientific decisions about
evascularization for ULM disease. The higher the patient
isk, the more likely that CABG improves survival. Con-
ersely, low-risk patients, especially those without bifurca-
ion disease, seem to be well suited for PCI with DES
mplantation.
ultivessel disease. The year 2008 started with an anti-
CI groundswell. The New York State database was ana-
yzed by Hannan et al. (74). This large, prominently
ublicized article reported on all New York State patients
ith multivessel disease who had PCI or CABG from January
003 to December 2004 and were followed up until December
005. A total of 9,965 patients underwent PCI, and 7,437
atients underwent surgery. Patients with ULM and AMI
ere excluded. Unadjusted survival was similar. After ad-
ustment for differences in baseline variables, CABG treated
atients with 3- and 2-vessel disease with proximal LAD
nvolvement had lower mortality. Park et al. (75) studied
,042 patients with multivessel disease treated from January
003 to December 2004. Unadjusted 3-year mortality was
igher for CABG (7.0% vs. 4.4%, p  0.01). Adjusted
ortality was similar. These 2 large registries show that
uch large differences are present in baseline severity of
llness and surgical and PCI outcomes that fundamental
cientific differences cannot be found without properly sized
andomized trials.
Two moderate-sized randomized trials presented mid-
erm follow-up. Booth et al. (76) followed up 988 patients
or 6 years who were treated with PCI (n  488) or CABG
n 500). Mortality was greater for PCI patients at 2 years,
nd this persisted at 6-year follow-up (10.9% vs. 6.8%, p 
.02). The ARTS (Arterial Revascularization Therapies
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Year in Interventional Cardiology June 2, 2009:2080–97tudy) investigators (77) followed up 607 multivessel DES-
reated patients for 3 years. Outcomes were compared with
urgical patients and non-DES stent patients in the ARTS
study. In addition, outcomes for the 159 diabetic patients
n ARTS II were compared with the ARTS I cohort. These
ata show that for ARTS-eligible patients, overall 3-year
urvival and 3-year risk of stroke is similar for DES,
on-DES, and CABG therapy. Differences in outcomes
ere greater in the diabetic subgroups. There was a trend
oward lower mortality for CABG and DES compared with
on-DES therapy. In addition, risk of cerebrovascular
ccident diverges for the 3 treatments. Daemen et al. (78)
rovide a meta-analysis of the ARTS I, ERACI II (Argentine
andomized Trial of Coronary Angioplasty with Stenting
ersus Coronary Bypass Surgery in Patients with Multiple
essel Disease), MASS II (Medicine, Angioplasty, or Surgery
tudy II), and SOS (Stenting Of Saphenous vein grafts) trials.
ive-year follow-up in the 3,051 patients randomized to stent
r surgery therapy are presented. Risk of death, stroke, and MI
as 16.7% vs. 16.9% (p  NS). Risk for TVR was higher for
he stent therapy (29% vs. 7.9%, p  0.001). For diabetic
atients, mortality trended higher in the PCI group (12.4% vs.
.9%, p  0.09).
Results of the 3-vessel disease subset of the SYNTAX
Synergy between Percutaneous Coronary Intervention with
axus and Cardiac Surgery) study were also presented;
,095 patients were randomized to CABG (n  549) or
ultivessel PCI with the Taxus DES (n  546) (79). At 1
ear there was no difference in the incidence of death, MI,
r stroke; however, the rate of revascularization was signif-
cantly higher in the PCI group (14.7% vs. 5.4%, p 
.001). The difference in MACE was greatest in patients
ith high baseline risk (SYNTAX score 33).
Finally, Pijls (80) presented results of the FAME (Frac-
ional Flow Reserve versus Angiography for Multivessel
valuation) trial, which randomized 1,005 patients with
tenoses 50% to angiography-guided PCI or fractional
ow reserve (FFR)-guided PCI. Patients in the FFR-
uided group were less likely to receive a stent (1.9 1.3 vs.
.7  1.2 stents/patient). At 1 year, patients in both groups
ad similar angina relief; however, the composite end point
f death, MI, or TVR was significantly lower in the FFR
roup (13.2% vs. 18.4%, p  0.02).
solated proximal LAD disease. Goy et al. (81) presented
0-year follow-up of 123 patients treated with PCI (n 52)
r CABG (n  59). MI-free survival was excellent at 90%
or both groups. PCI patients had a 26% rate of TVR,
hereas no CABG-related patients required TVR at 10-
ear follow-up. Kapoor et al. (82) performed a meta-analysis
f 9 randomized trials of PCI or CABG for proximal LAD
isease (633 PCI-treated patients, 577 CABG-treated pa-
ients). The 5-year survival was similar (92.8% vs. 90.6%);
VR was higher for PCI (33% vs. 7.3%). Angina relief was
reater with CABG.
CI versus medical therapy. Holmes (83) provided an
xcellent review of the subject and concluded that PCI (rovides superior angina relief versus medical therapy, but
oes not prevent MI or death. Weintraub et al. (84)
onfirmed these findings in a quality-of-life analysis from
he COURAGE (Clinical Outcomes Utilizing Revascular-
zation and Aggressive Drug Evaluation) trial. Angina relief
nd quality of life was better initially for PCI therapy, but
his benefit disappeared at 3 years. Both authors conclude
hat for patients with stable coronary artery disease and mild
r no symptoms, initial medical therapy is an acceptable
lternative to initial PCI therapy. Schomig et al. (85)
erformed a meta-analysis of 17 randomized trials comparing
CI and medical therapy. Unlike the COURAGE trial,
chomig included stable post-MI patients. In this analysis,
ortality was lower for PCI therapy, especially in patients
ith recent MI who had angina or exercise-induced
schemia.
o surgery on site. There has been debate about the safety
nd results of PCI at facilities without on-site cardiac
urgery. In one of the largest series to date, Frutkin et al.
86) reported outcomes of 1,090 elective PCIs performed at
hospital without cardiac surgery. A low incidence of
omplications was observed, and only 2 patients required
ransfer for emergency CABG. It is important to note that
his center has highly experienced interventionalists and
ell-defined protocols for transfer.
utcomes research. In 2008, there were many reports
ddressing clinical outcomes after PCI. Singh et al. (87)
tudied sex differences in mortality after PCI among 18,885
atients treated at the Mayo Clinic. A significant improve-
ent in survival was seen for both men and women over the
ast 25 years. After adjustment for baseline risk, no differ-
nce in short- or long-term mortality was observed between
en and women. In another report, Singh et al. (88)
rovided validation for the new Mayo Clinic Risk Score
odel in a large patient cohort from the NCDR. This risk
core, which uses 7 simple clinical and noninvasive variables,
rovides clinicians an excellent tool for risk assessment and
ecision making before diagnostic angiography.
Rao et al. (89) studied trends in use of the radial approach
or PCI. Among 593,094 patients, radial PCI was per-
ormed in only 1.32% of total procedures, although an
ncrease was observed in 2007. Lower rates of bleeding and
ascular complications were seen with the radial approach.
Applegate et al. (90) examined trends in vascular com-
lications after diagnostic catheterization and PCI in 35,016
rocedures from 1998 to 2007. A significantly lower inci-
ence of vascular complications was observed during this
ime, which the investigators attributed to improvements in
rocedural factors such as use of fluoroscopy-guided femoral
ccess and smaller sheath sizes. Similarly, Doyle et al. (91)
eported a marked decline in the incidence of major femoral
leeding after PCI over the past decade. The relationship
etween peri-procedural bleeding and 1-year outcome was
mphasized in a report from Ndrepepa et al. (92). Bleeding
ithin 30 days independently predicted 1-year mortalityhazard ratio: 2.96, p  0.001).
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June 2, 2009:2080–97 Year in Interventional CardiologyTwo studies evaluated the impact of pre-procedural
ardiac troponin levels on outcome after PCI (93,94). Both
tudies showed that baseline elevation of the cardiac tropo-
in level is an important predictor of ischemic complications
nd prognosis. In another report, Wang et al. (95) found
hat the majority of hospitals in the U.S. do not systemat-
cally assess cardiac markers after elective PCI. As expected,
ospitals that routinely performed biomarker testing had
igher rates of periprocedural MI; however, these hospitals
ad a trend toward lower mortality and greater adherence to
ecommended medications.
From et al. (96) examined outcomes in 138 nonagenarians
ndergoing PCI and observed high technical success and good
linical outcomes in carefully selected patients. In other reports,
ercado (97) found that urinary dipstick proteinuria was
ndependently associated with mortality in patients undergoing
CI. Kip et al. (98) highlighted the wide heterogeneity in
efinition of the term MACE, and recommend that investi-
ators design separate composite end points for evaluation of
afety and effectiveness outcomes.
ifurcation disease. Percutaneous treatment of bifurcation
isease remains challenging. Ormiston et al. (99). provided
nsight into crush bifurcation stenting and post-dilation
trategies using microcomputed tomography in bench de-
loyments. Importantly, less side-branch ostial stenosis was
bserved with 2-step kissing post-dilation, the minicrush
echnique compared with conventional crush, and use of
tents with larger cell size (3.5 mm).
Three clinical trials evaluating treatment of bifurcation
esions were presented at the Transcatheter Cardiovascular
herapeutics conference. The BBC-ONE (British Bifurca-
ion Coronary study: Old, New and Evolving strategies)
tudy (100) randomized 500 patients with bifurcation le-
ions to complex stenting (crush or culotte) or simple
tenting (main vessel with provisional T-stent) using the
axus stent. At 9 months, the primary end point, a
omposite of death, MI, and target vessel failure, was
ignificantly lower in the simple stent arm (8.0% vs. 15.2%,
 0.009). Stent thrombosis was higher with complex
tenting (2.0% vs. 0.4%). In another study, Routledge et al.
101) also showed excellent clinical outcomes associated
ith a simple stent strategy. Among 424 consecutive pa-
ients, the provisional side-branch stent strategy was used in
2% of patients with a high initial success rate, and a low
ate of MACE at 2 years (13.6%). This important shift in
hinking to use a 1-stent technique as the default for most
atients was further emphasized in a review by Latib and
olombo (102).
The Nordic Bifurcation Stent Technique study (103)
ompared outcomes with the crush and culotte stent strat-
gies in 424 patients using the Cypher (Cordis Corp.,
iami, Florida) SES. There was no difference in clinical
utcomes at 6 months. Angiographic follow-up at 8 months
howed a very low rate of restenosis in the main vessel with
ither stent technique, but a higher restenosis rate in the
ide branch with the crush technique (9.8% vs. 3.8%). bThe DIVERGE (Drug-Eluting Stent Intervention for
reating Side Branches Effectively) trial (104) evaluated the
xxess biolimus A9-eluting stent in 302 patients. At 9
onths there was a low rate of MACE (7.7%) and ischemic
LR (4.3%) with this novel self-expanding stent.
ein graft disease. The AMEthyst (Assessment of the
edtronic AVE Interceptor Saphenous Vein Graft Filter
ystem) trial (105) compared use of the Interceptor PLUS
oronary Filter System (Medtronic Vascular, Santa Rosa,
alifornia) with approved devices during vein graft inter-
ention. At 30 days the primary end point MACE occurred
n 8% of Interceptor and 7.3% of control patients, thus
howing noninferiority of this novel embolic protection
evice.
Two studies evaluated determinants of adverse outcome
fter vein graft PCI. In a pooled analysis of 3,958 patients,
oolong et al. (106) identified angiographic variables,
ncluding saphenous vein graft (SVG) degeneration and
stimated plaque volume, as the strongest predictors of
0-day MACE. Similarly, Kirtane et al. (107) found that
esion length was the strongest correlate of outcome in a
ubstudy of the PRIDE (PRotection during saphenous vein
raft Intervention to prevent Distal Embolization) trial.
dditionally, both analyses confirmed a clear benefit of
mbolic protection across a range of angiographic risk,
ncluding patients with relatively short lesions.
hronic occlusion. Safley et al. (108) studied long-term
urvival in 2,608 patients undergoing PCI for chronic total
cclusion (CTO). Notably, successful PCI for CTO of the
AD was associated with an improved 5-year survival;
owever, there was no difference in outcome for successful
ecanalization of the circumflex or right coronary arteries.
o evaluate the physiologic effect of CTO revascularization,
heng et al. (109) performed serial cardiac MRI in 17
atients undergoing CTO PCI. Successful PCI resulted in
significant increase in myocardial blood flow and contrac-
ility at 24 h that persisted at 6 months. Courtney et al.
110) published an excellent review article describing the
ole of cardiac imaging techniques in assisting with patient
election for PCI, as well as innovative technologies that
ay enhance procedural success.
irect stenting. Two studies published in 2008 showed a
enefit of direct stenting compared with stenting after
re-dilation. Ormiston et al. (111) found that direct stent-
ng with the Taxus Liberté PES in carefully selected lesions
as associated with significantly reduced procedural time,
rocedural complications, and possibly restenosis. In a small
andomized trial, Cuisset et al. (112) measured microcircu-
atory resistance with an intracoronary pressure/temperature
ensor-tipped guidewire and found less microcirculatory
ysfunction in patients with stable angina treated with
irect stenting compared with conventional stenting.
adiation safety. There has been increasing awareness
bout radiation exposure to the interventionalist. Brasselet
t al. (113) compared radiation dosage to the operator
etween femoral and radial coronary procedures. Radiation
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Year in Interventional Cardiology June 2, 2009:2080–97xposure to operators was significantly higher using the
adial approach compared with the femoral approach de-
pite optimizing radiation protection. This study clearly
ighlights the need for novel radiation protection systems to
educe operator risk.
ES
tent thrombosis. In a registry of 8,146 patients treated
ith DES, stent thrombosis was observed in 3.3% at 4 years
114). Diabetes was predictive of early stent thrombosis,
hereas ACS, younger age, and use of PES were associated
ith late stent thrombosis. In a Spanish registry of 23,500
atients treated with DES, stent thrombosis was observed
n 2% at 3 years (115). Predictors of early stent thrombosis
ncluded diabetes and renal failure; both early and late stent
hrombosis was increased in patients with ACS, LAD
tenting, and longer stent length.
Based on predictors of stent thrombosis, Baran et al.
116) developed a risk score (discontinuation of thienopy-
idine 6 months, diabetes mellitus, lesion length 28
m, multiple stents, vessel 3 mm diameter, calcification,
r left main stent). Stent thrombosis occurred in 0.8% of
ow-risk patients, 3.6% of medium-risk patients, and 12.6%
f high-risk patients.
Although the Endeavor (Medtronic, Santa Rosa, Cali-
ornia) DES was thought to have low rates of stent
hrombosis, a registry of 3,680 patients treated with second-
eneration DES (117) found no difference in stent throm-
osis rates between Xience (Abbott Vascular, Santa Clara,
alifornia) and Endeavor DES. Of concern, Maeng (118)
eported 6,122 patients treated with Endeavor or SES in the
estern Denmark Heart Registry and found that adjusted
ates of death, TVR, and stent thrombosis were higher with
ndeavor.
SORT OUT III (The Danish Organization on Random-
zed Trials with Clinical Outcome), a randomized trial of
,333 patients, found higher rates of stent thrombosis, MI,
nd TVR with Endeavor compared with SES (119). Reas-
uringly, the SORT OUT II trial found no differences in
ACE among 2,098 patients randomized to SES versus
ES (120).
echanisms of DES thrombosis. Numerous articles were
ublished in 2008 attempting to elucidate mechanisms of
tent thrombosis. In a porcine model, overlapping PES
esulted in marked intramural thrombi and impaired vaso-
eactivity (121). An intravascular ultrasound substudy of the
axus trials found that PES was associated with reduced
ntimal hyperplasia but expansive remodeling at 9 months
122), possibly contributing to late malapposition.
Acute stent malapposition was observed in 35% of
TEMI patients undergoing DES or BMS, and late stent
alapposition was observed in DES patients because of
ositive remodeling (123). An autopsy study (124) sug-
ested that delayed healing and stent thrombosis occurred
ore frequently when DES was placed in unstable com- oared with stable plaques. An optical coherence tomography
tudy (125) found that neointimal coverage improved
etween 3 and 24 months, but the majority of DES still
ad some uncovered struts. A rabbit study (126) sug-
ested that delayed healing was caused by the polymer
not the drug) on the DES. Another rabbit study (127)
ound that everolimus-eluting stent had superior endo-
helialization compared with SES, PES, or ZES. Finally,
rst-generation DES have been associated with endothe-
ial dysfunction distal to the stent (128 –130), and this
ay be improved with second-generation DES (131).
hese data suggest that newer-generation stents may
mprove endothelialization and vasomotor dysfunction.
ate outcome of DES versus BMS. The New York State
egistry (132) compared 11,436 patients treated with BMS
before the release of DES) and 12,526 patients treated with
ES. The risk-adjusted 2-year outcomes were favorable in
he DES group, including improved nonfatal MI and TVR;
ortality rates were similar. Likewise, the Medicare data-
ase (133) found reduced rates of repeat PCI, CABG, and
TEMI after stenting in the DES era (61.5% received
ES, 38.5% BMS) compared with the BMS era. Another
edicare analysis of 76,525 patients who received DES
134) was compared with 2 matched cohort control groups.
he DES patients were found to have improved survival as
ell as reduced TVR and MI compared with both BMS
ohorts. The Massachusetts registry (135) compared 11,556
ES patients and 6,237 BMS patients. Two-year risk-
djusted outcomes were superior in the DES group, includ-
ng mortality (9.8% vs. 12.0%, p  0.0002), MI (8.3% vs.
0.3%, p  0.0005), and TVR (11.0% vs. 16.8%, p 
.0001). The Cleveland Clinic group (136) examined 832
atients who died over a 4.5-year follow-up after stenting.
hey reported that DES-treated patients had lower all-
ause mortality in unadjusted and adjusted Cox proportional
odels and propensity-matched groups.
ff-label use of DES. Several groups reported comparisons
f DES versus BMS in off-label applications (137–142). In
eneral, off-label use of both DES and BMS are associated
ith higher event rates compared with on-label use (consistent
ith higher-risk clinical and lesion characteristics). However,
ES seemed to have similar or improved rates of death or MI
ompared with BMS, and consistently reduced need for TVR.
verall, these data support the use of DES for off-label
ndications.
ES in diabetic patients. Diabetes is a powerful predictor
f adverse clinical and angiographic events after PCI. Three
eparate registries compared DES with BMS in diabetic
atients and found reduced TVR with similar or improved
ates of MI or death (143–145). Subgroup analysis from
andomized trials of DES versus BMS found markedly
ower rates of TVR, with similar rates of death, MI, and
tent thrombosis at 4 years (146). A meta-analysis of registries
nd randomized trials including more than 11,000 diabetic
atients reported revascularization rates of 10% with similar
utcomes comparing PES and SES (147). Conversely, a
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June 2, 2009:2080–97 Year in Interventional Cardiologyubgroup analysis of the SIRTAX (Sirolimus-Eluting versus
aclitaxel-Eluting Stents for Coronary Revascularization) trial
148) showed reduced TVR with SES compared with PES,
nd a prospective trial randomizing 400 diabetic patients to
ES versus PES (149) found reduced angiographic restenosis
t 6 months (3.4% vs. 18.2%, p  0.001) and TVR at 9
onths (2.0% vs. 7.5%, p  0.017) after SES.
ES in vein grafts. Saphenous vein graft interventions
emain a higher-risk subgroup for PCI. Pucelikova et al.
150) reported 110 patients undergoing SVG stenting
DES in 91%). At 1 year, death occurred in 7.4%, TVR in
9.0%, and MACE in 30.5%. Predictors of MACE in-
luded thrombus and length of stented segment. Okabe
t al. (151) reported a retrospective series of 138 patients
reated with DES in SVG compared with 344 patients
reated with BMS to SVG. At 1 year, there was no
dvantage to DES with regard to death, MI, or TVR. The
OS study (152) randomized 80 patients to undergo stent-
ng of SVG with PES versus BMS. The lesions were
elatively focal with mean stent length 16  6 mm. At
2-month angiography, late loss and restenosis (9% vs. 51%,
 0.0001) favored PES, and at 1.5-year follow up, TLR
as reduced (5% vs. 28%, p  0.003).
ES for in-stent restenosis. Long-term (3 years)
ollow-up of a trial that randomized 150 patients with
n-stent restenosis to SES versus percutaneous transluminal
oronary angioplasty (153) reported that stent thrombosis
as similar in the 2 groups but event-free survival was
uperior with SES (76% vs. 65%, p  0.019). The 24-
onth follow-up of the Taxus V in-stent restenosis trial
154) found reduced TLR with PES compared with brachy-
herapy (18.1% vs. 27.5%, p  0.03) with similar rates of
eath, MI, and stent thrombosis. In another trial, Holmes
155) also found improved outcomes with SES versus
rachytherapy at 3-year follow-up.
ew Stent Technologies
ew DES and polymers. In 2008, there were several
ublications of new DES technologies. In the SPIRIT III
rial, 1,002 patients were randomly assigned to receive either
n everolimus-eluting stent or a PES (156). The primary
nd point, angiographic in-segment late loss at 8 months,
as significantly less in the everolimus stent group (0.14
m vs. 0.28 mm, p  0.004). The rate of MACE at 9 and
2 months was lower in the everolimus group. In a small
andomized trial, a novel ZES (ZoMaxx, Abbott Labora-
ories, Abbott Park, Illinois) resulted in significantly greater
ate lumen loss compared with a PES (157).
Turco et al. (158) studied outcomes with the thinner-
trut Taxus Liberté stent compared with the Taxus Express
tent. In small vessels and long lesions, lower rates of
estenosis were observed with the Liberté DES.
Several trials evaluated new DES technologies with
iodegradable polymers or polymer-free stents. These new-
eneration stents were designed to improve the safety profile Cf first-generation DES. Windecker et al. (159) randomized
,707 patients to a novel biolimus-eluting stent with a
iodegradable polymer or SES (with durable polymer). At 9
onths, the biolimus-eluting stent was noninferior to the
ES for the composite clinical end point. Byrne (160)
tudied a novel polymer-free dual probucol and rapamycin–
luting stent. Angiographic restenosis and late loss were
imilar to a permanent polymer SES, but superior to a ZES.
n the ISAR-TEST 3 (Intracoronary Stenting and Angio-
raphic Restenosis–Test Efficacy of Rapamycin-eluting
tents with Different Polymer Coating Strategies) trial,
ehilli et al. (161) compared 3 rapamycin-eluting stents
biodegradable polymer vs. permanent polymer vs. polymer-
ree). The biodegradable SES had a similar rate of angio-
raphic late loss to the permanent polymer stent; however,
he polymer-free stent had a significantly higher late loss
0.17 mm vs. 0.23 mm vs. 0.47 mm, respectively). Jabara et
l. (162) showed improved vascular healing in an animal
odel using a new DES with a slow-release biodegradable
olylactide polymer and low-dose paclitaxel. In a first-
n-man study, Costa et al. (163) evaluated a novel stainless-
teel platform with a nanothin-microporous hydroxyapatite
urface coating impregnated with a polymer-free sirolimus
ormulation (Vestasync-eluting stent, MIV Therapeutics,
nc., Atlanta, Georgia). At 4 months, in-stent late loss was
.30  0.25 mm). No adverse events were observed at 6
onths.
In contrast to these promising results, a randomized trial
valuating the CoStar DES (Conor MedSystems, Menlo
ark, California) (164) found that this novel platform was
ot noninferior to a Taxus DES. At 8 months, the inci-
ence of MACE (11.0% vs. 6.9%, p  0.005) and late loss
0.49 mm vs. 0.18 mm, p  0.0001) were significantly
igher with the CoStar stent.
ioabsorbable stents. There has been tremendous interest
n fully biodegradable coronary DES. Ormiston et al. (165)
eported findings from a 30-patient study using a bioab-
orbable everolimus-eluting stent that has a backbone of
oly-L-lactic acid. At 6 months, angiographic late loss was
.44 mm, mainly because of a mild reduction of the stent
rea, with minimal neointimal hyperplasia. Device success
as 94%. This study represents a major step forward in
linical investigation of bioabsorbable stent technologies.
harmacotherapy
lopidogrel. Given the short door-to-balloon times, some
ave questioned the benefit of pre-treatment with clopi-
ogrel before primary PCI. Vlaar et al. (166) performed a
eta-analysis of all primary PCI trials with core laboratory
ngiographic reviews in which pre-treatment status with
lopidogrel was known (n 8,429). In multivariate analysis,
re-treatment with clopidogrel was an independent predic-
or of early reperfusion (OR: 1.51, 95% confidence interval:
.31 to 1.74, p  0.0001) and improved clinical outcome.
onversely, the PRAGUE-8 trial (167) randomized 1,028
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Year in Interventional Cardiology June 2, 2009:2080–97atients with stable angina to pre-treatment with 600 mg
lopidogrel 6 h before catheterization versus selective
dministration after initial angiography showed the need for
CI. Pre-treatment with a high loading dose was associated
ith increased bleeding risk, but no difference in ischemic
nd points. However, this study was underpowered given
he low event rate (0.8%).
Other studies have shown that 600-mg loading doses of
lopidogrel achieve stronger platelet inhibition compared
ith conventional regimens (168). Even patients on chronic
lopidogrel therapy have improved platelet inhibition if
eloaded with clopidogrel (169). Moreover, the ARMYDA
Antiplatelet therapy for Reduction of MYocardial Damage
uring Angioplasty) Reload trial (170) showed that ACS
atients on chronic clopidogrel therapy benefited from
00-mg reload. The primary end point of 30-day death, MI,
r TVR was significantly reduced in the reload group (7%
s. 18%, p  0.035).
Clopidogrel hyporesponsiveness continued to be an im-
ortant topic in 2008. Gori et al. (171) showed that dual
onresponsiveness to both aspirin and clopidogrel was
nfrequent (6%) but identified patients at high risk of DES
hrombosis or death. Studies utilizing the Accumetrics (San
iego, California) device (a more rapid and specific measure
f P2Y12 responsiveness) found that pre-PCI (172) and
ost-PCI (173) platelet reactivity was associated with
ACE. Increasing the clopidogrel dose in patients who
ere resistant to the first 600-mg load (vasodilator-
timulated phosphoprotein index 50%) was found to be
afe and improved clinical outcomes (174).
Although a number of factors may influence clopidogrel
yporesponsiveness, Trenk et al. (175) found a genetic
re-disposition that influenced the cytochrome P450–
ependent conversion of clopidogrel to its active metabolite.
xternal influences may include smoking, which increases
ctive metabolites (176), or medications, such as the proton
ump inhibitor omeprazole, which decreased the antiplate-
et effect of clopidogrel (177).
rasugrel. More potent or more-rapid-acting oral anti-
latelet regimens seem to be superior to conventional dual
ntiplatelet therapy with clopidogrel and aspirin. In the
RITON–TIMI (TRial to Assess Improvement in Thera-
eutic Outcomes by Optimizing Platelet InhibitioN with
rasugrel–Thrombolysis In Myocardial Infarction) 38 trial
178), prasugrel plus aspirin was superior to clopidogrel plus
spirin with regard to stent thrombosis (1.13% vs. 2.35%,
 0.0001) and the primary end point of cardiovascular
eath, MI, or stroke (9.7% vs. 11.9%, p  0.0001).
ignificant advantages of prasugrel were observed regardless
f whether patients received DES (n  5,743) or BMS
n  6,461). Because prasugrel was associated with more
leeding than clopidogrel, a landmark analysis (179) found
hat net clinical benefit favored prasugrel both early (day 0
o 3) and later (day 3 to end of trial).
ilostazol. Triple antiplatelet therapy (adding cilostazol tolopidogrel  aspirin) has previously been shown to reduce flatelet aggregation and restenosis. Park (180) reported a
egistry of 3,099 patients undergoing successful DES place-
ent who were treated with triple (n  1,443) or dual (n 
,656) antiplatelet therapy. After adjustment for selection
ias (multiple high-risk features were more common in the
ilostazol group), triple antiplatelet therapy was associated
ith reduced stent thrombosis and MI. Lee et al. (181)
andomized 400 diabetic patients treated with DES to
eceive triple (with cilostazol) versus dual antiplatelet ther-
py. Triple antiplatelet therapy significantly reduced angio-
raphic restenosis at 6 months (8.0% vs. 15.6%, p  0.03),
-month TLR (2.5% vs. 7.0%, p  0.03), and MACE
3.0% vs. 7.0%, p  0.066).
ivalirudin. Several studies examined the use of bivaliru-
in during PCI. Bivalirudin was found to be cost effective
ompared with UFH and GP IIb/IIIa (182). One-year
ollow-up of the ACUITY (Acute Catheterization and
rgent Intervention Triage Strategy) trial found similar
ates of ischemia and mortality but a trend for higher rates
f MI in the bivalirudin arm (9.3% vs. 7.8%, p  0.06)
ompared with UFH and GP IIb/IIIa (183,184).
The ARNO (Antithrombotic Regimens aNd Outcome)
rial (185) randomized 900 patients undergoing PCI to
ivalirudin versus UFH 100 /kg; both groups were pre-
reated with clopidogrel and had immediate sheath removal
nd closure devices. Bivalirudin was associated with a
eduction in major bleeding and improved net clinical
enefit. The NAPLES (Novel Approaches for Preventing
r Limiting Event Study) trial (186) randomized 335
iabetic patients pre-treated with clopidogrel to bivalirudin
ersus UFH with tirofiban. At 30 days, ischemic events were
imilar and bleeding was reduced in the bivalirudin arm.
eit et al. (187) reported similar results from subgroup
nalysis of diabetic patients from the ACUITY trial.
The ISAR-REACT 3 trial (188) randomized 4,570
atients pre-treated with 600 mg clopidogrel to UFH versus
ivalirudin. Net clinical benefit was not different between
he 2 groups, but bleeding was lower with bivalirudin (3.1%
s. 4.6%, p  0.008).
Finally, given concerns about the early increase in isch-
mic events observed in bivalirudin patients not adequately
re-treated with clopidogrel, Cortese (189) reported a study
f 178 patients requiring complex PCI who were random-
zed to conventional versus prolonged (4 h post-PCI)
nfusion of bivalirudin. Bleeding rates were similar (87%
adial access), but reduced post-PCI MI was observed with
he prolonged infusion.
ondaparinux. Mehta et al. (190) pooled the OASIS
Organization to Assess Strategies in Ischemic Syndromes)
and 6 trials comparing fondaparinux with heparin (or
noxaparin) and reported a beneficial effect in patients
reated with an invasive (cardiac catheterization) strategy.
owever, among patients undergoing PCI, there was a
ignificant increased risk of catheter thrombosis with
ondaparinux compared with enoxaparin (OR: 3.98, 95%
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June 2, 2009:2080–97 Year in Interventional Cardiologyonfidence interval: 1.74 to 9.09) and compared with UFH
OR: 8.98, 95% confidence interval: 1.14 to 71.43).
o antithrombin therapy. The CIAO (Coronary Inter-
entional Antiplatelet-based Only) study (191) randomized
00 stable angina patients with uncomplicated lesions who
ere pre-treated with aspirin and clopidogrel to heparin
ersus placebo. Catheters were flushed with heparinized
aline (up to 100 times per procedure) and procedure times
ere short (mean 11 min). Bleeding and clinical events were
educed in the no heparin arm, suggesting that antithrom-
ins may be unnecessary in highly selective, simple elective
CI cases.
atients on warfarin. There are few data regarding man-
gement of PCI patients requiring long-term anticoagula-
ion with warfarin. Karjalainen et al. (192) reviewed out-
omes in 241 PCI patients (80% femoral approach). Mean
nternational normalized ratio at PCI was 2.2  0.5. Access
ite complications and major bleeding occurred in 5.0% and
.2% of patients, respectively. These data suggest that
ninterrupted anticoagulation is a reasonably safe approach
n carefully selected patients. Rossini et al. (193) studied
utcomes in patients requiring triple therapy compared with
ual antiplatelet therapy alone. As expected, bleeding was
ore frequent in patients with triple therapy; however, this
xcess risk was seen mostly in patients with an international
ormalized ratio 2.6.
ontrast Nephropathy
esults of 2 randomized trials evaluating the effect of
odium bicarbonate infusion for prevention of contrast-
nduced nephropathy (CIN) were published in 2008
194,195). Both trials enrolled patients with stable renal
ysfunction (creatinine clearance 60 ml/min) undergoing
oronary angiography or PCI. Compared with saline infu-
ion alone, there was no difference in the incidence of CIN
ith bicarbonate in either trial. A 1,307-patient meta-
nalysis by Hogan et al. (196) suggested a possible benefit of
icarbonate; however, this study was limited by marked
eterogeneity and probable publication bias, and did not
nclude data from the largest randomized trial by Maioli et
l. (195). Kane et al. (197) provided a report emphasizing
he importance of minimizing contrast dose in patients with
enal dysfunction, and showed a very low rate of CIN in
hose who receive ultra-low-dose contrast. Harjai et al.
198) compared the value of 4 different definitions for CIN
ommonly used in studies and found that only 2 (serum
reatinine 25% and serum creatinine 0.5 mg/dl) were
onsistently predictive of clinical outcomes. Based on these
ata, a novel nephropathy grading system was developed to
redict 6-month events. Stone (199) reported findings from
f a trial evaluating systemic cooling to prevent CIN.
nfortunately, only 136 of the planned 400 patients were
nrolled because the study sponsor became insolvent. Cool-
ng was safe and well tolerated, but no benefit of hypother-ia was observed. Finally, McCullough (200) provided an oxcellent review article on contrast-induced acute kidney
njury, covering pathogenesis, risk assessment, prevention,
nd management of CIN.
eripheral Vascular Disease
HA Conference on Atherosclerotic Vascular Disease.
roceedings of the second AHA Conference on Atheroscle-
otic Vascular Disease were published in 2008 (201–209). The
eport includes 8 excellent summaries of areas that were
ddressed at the symposium, including nomenclature for ath-
rosclerotic vascular disease, screening, magnetic resonance and
omputed tomographic imaging, stroke intervention, carotid
rtery revascularization, abdominal aortic aneurysm repair,
ower-extremity revascularization, and renal artery disease.
eaders are referred to the proceedings for detailed informa-
ion on these subjects.
arotid disease. There has been controversy about the
afety of carotid stenting. Gurm et al. (210) performed a
eta-analysis of 5 trials with 2,122 patients undergoing
tenting or endarterectomy for symptomatic carotid disease.
here was no difference in the risk of 30-day mortality,
troke, or disabling stroke among patients randomized to
ither strategy. In another report, Iyer (211) presented
-year outcomes of the BEACH (Boston Scientific EPI:
Carotid Stenting Trial for High-Risk Surgical Pa-
ients) trial, which evaluated high-surgical-risk patients
ndergoing stenting with the Wallstent plus FilterWire
mbolic protection device (Boston Scientific, Minneapo-
is, Minnesota). At 1 year, the primary composite end
oint occurred in 8.9% of patients; this rate was nonin-
erior to outcomes in similar patients after surgical
ndarterectomy.
Two trials investigating new embolic protection devices
or carotid artery stenting were presented at the Transcath-
ter Cardiovascular Therapeutics conference (212,213). The
PIC (Evaluating the Use of the FiberNet Embolic Pro-
ection System in Carotid Artery Stenting) trial evaluated
he FiberNet (Lumen Biomedical, Plymouth, Minnesota)
mbolic Protection System (212), whereas the EMPIRE
A Multicenter Registry Evaluating Neuroprotection Dur-
ng Carotid Stenting with a Novel Flow Reversal System)
rial evaluated the GORE (WL Gore and Associates) Flow
eversal System (213). Both studies showed a high proce-
ural success and low rate of stroke and major adverse events
t 30 days.
Schofer et al. (214) assessed the timing of embolic events
fter carotid stenting with serial magnetic resonance imag-
ng; 20% of patients had ipsilateral injury at 3.5 h. Of note,
7% of patients had further evidence of emboli occurring
etween 3.5 and 18 h after embolic-protected stenting,
nvolving both hemispheres. Causes of late embolization
emain unclear but may be related to manipulation of
atheters in the aortic arch.
Lin et al. (215) provided a report on feasibility and
utcomes after endovascular recanalization for chronic cer-
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Year in Interventional Cardiology June 2, 2009:2080–97ical internal carotid artery occlusion. Successful recanaliza-
ion was achieved in 35 of 54 patients (65%). Two patients
ad a stroke (4%), and vascular complications occurred in 3
atients, including 1 late pseudoaneurysm, 1 carotid-
avernous fistula, and 1 extravasation. Finally, Levy et al.
216) published a comprehensive review on the treatment of
arotid artery disease.
enal stenting. Cooper et al. (217) investigated whether
djunctive use of an embolic protection device (Angio-
uard, Cordis, Miami, Florida) or GP IIb/IIIa receptor
nhibitor (abciximab) during renal artery stenting would
mprove renal function. At 1 month, a decline in renal
unction was observed with stenting alone, stenting with
mbolic protection, and stenting with abciximab alone.
owever, with combination therapy no change in renal
unction was noted.
Mahmud et al. (218) reported a novel angiographic
ethod for assessing renal microvascular perfusion—the
enal frame count and renal blush grade. Both parameters
ere impaired in hypertensive patients with unilateral renal
rtery stenosis, and improved after stenting. Reduction in
enal frame count was associated with a blood pressure
eduction.
uperficial femoral artery disease. Two studies published
n 2008 investigated use of paclitaxel-coated angioplasty
alloons to limit restenosis during endovascular treatment of
emoropopliteal disease. Tepe et al. (219) randomized 154
atients to a paclitaxel-coated balloon, uncoated balloon
ith paclitaxel dissolved in the contrast medium, or un-
oated balloon alone. At 6 months, late lumen loss (the
rimary end point) and the rate of revascularization was
ignificantly lower in the group treated with the paclitaxel-
oated balloon. No benefit was seen with paclitaxel in the
ontrast medium. In another smaller randomized trial,
imilar benefits were also observed with a paclitaxel-coated
alloon (220).
tructural Heart Disease
ercutaneous aortic valve replacement. Percutaneous aor-
ic valve replacement has emerged as a promising new treat-
ent option for aortic stenosis. Grube et al. (221) reported
utcomes in 136 patients treated with the CoreValve (Core-
alve Inc., Irvine, California) prosthesis. Procedural success
ith the third-generation valve was 91.2%, and there was a
ow rate of death, stroke, or MI at 30 days (14.7%). A
arked improvement in functional status was observed. A
ase report (222) of a patient who died 425 days after
mplant of a CoreValve showed ingrowth of tissue covering
he lower part of the valve situated in the LV outflow tract.
chofer et al. (223) published results of a first-in-man study
ith the novel repositionable prosthesis in high-surgical-
isk patients with severe aortic stenosis (Direct Flow Med-
cal, Santa Rosa, California). Valve implantation was
chieved in 12 of 15 patients and was associated with a
easonable safety profile. Two reports described new left tundle branch block and atrioventricular block after percu-
aneous valve implantation (224,225). In the series by Webb
225), 7 of 123 (5.7%) patients required a permanent
acemaker. In another report, Babaliaros et al. (226) re-
orted the use of balloon aortic valvuloplasty to help size the
nnulus before valve implantation. Zegdi et al. (227) provided
mportant observations regarding post-deployment character-
stics of a self-expanding valve stent in 35 patients under-
oing surgical valve replacement. In bicuspid valves, the
tent was often distorted and underdeployed, which may
nfluence valve results and durability. Chiam et al. (228) and
ebb (229) provided nice review articles on transcatheter
ortic valve implantation. Finally, Vahanaian et al. (230)
ublished a position statement on transcatheter aortic valve
mplantation from the European Association of Cardio-
horacic Surgery and European Society of Cardiology. The
ocument summarizes current techniques and results, as
ell as recommendations for patient selection, performance
f valve implantation, and evaluation of procedural results.
itral valve repair. Sorajja et al. (231) reported a novel
ethod of percutaneous mitral valve repair in which an
nnulus reduction device is implanted into the myocardium
t the posteromedial mitral annulus via the coronary sinus.
significant reduction in mitral annular area was observed,
hich persisted at 3 months. Compared with other coronary
inus technologies, this technique may be advantageous
hen the coronary sinus lies superior to the mitral annulus,
nd also may lessen risk of injury to the circumflex artery.
ulmonary valve replacement. Lurz et al. (232) published
esults with a percutaneous pulmonary valve in 155 patients
ith pulmonary conduit stenosis or regurgitation. Most
atients had tetralogy of Fallot. Valve implantation was
chieved with a very high success rate, and freedom from
eoperation was 70% at 70 months.
atent foramen ovale (PFO). A randomized trial of PFO
losure in 432 patients with migraine (STARflex device,
MT Medical Inc., Boston, Massachusetts) (233) found no
ifference in cessation of migraine headache, and patients in
he implantation arm had more serious adverse effects.
aafe et al. (234) performed a randomized trial in 660
atients comparing 3 PFO closure devices. Excellent out-
omes were achieved with all devices; however, patients
reated with the Helex (WL Gore and Associates, Flagstaff,
rizona) devices were more likely to have a residual shunt at
0 days compared with the other devices. In another study,
ildick-Smith et al. (235) reported that many PFO closure
rocedures can be performed safely with fluoroscopy alone.
lcohol septal ablation (ASA). Three articles in 2008
ddressed outcomes after ASA for hypertrophic cardiomy-
pathy (236–238). All studies showed a reduction in LV
utflow tract gradient with ASA and improvement in
unctional class. Death occurred in 1% to 1.4%, and pace-
aker implantation was required in 8.2% to 26%. In the
ayo series, the procedural complication rate was higherhan that in matched controls who underwent surgical
m
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